Most new drugs do little good, study finds

James Thirst
Wednesday 18 August 2010 00:00
Comments

Drug companies have been accused of conning the public by hyping up patented medicines with little new to offer while downplaying their side-effects.

A study concluded that up to 85 per cent of new drugs offered few if any new benefits while having the potential to cause serious harm due to toxicity or misuse.

The author of the research, Donald Light, professor of comparative health policy at the University of Medicine and Dentistry in New Jersey, said: “Sometimes drug companies hide or downplay information about serious side-effects of new drugs and overstate the drugs’ benefits. Then, they spend two to three times more on marketing than on research to persuade doctors to prescribe these new drugs. Doctors may get misleading information and then misinform patients about the risks of a new drug.”

Professor Light presented his paper, entitled “Pharmaceuticals: A Two-Tier Market for Producing ‘Lemons’ and Serious Harm”, yesterday at the American Sociological Association’s annual meeting in Atlanta, Georgia.

The study includes data from independent reviewers which suggest that 85 per cent of new drugs provide few, if any, new benefits.

Hyping a drug began with clinical trials designed to minimise evidence of harm and published literature that emphasised its advantages, said Professor Light.

Building on this foundation, pharmaceutical companies staged massive campaigns to sell the product, when a controlled limited launch would allow evidence of its effects to be gathered, he argued.

He accused companies of conducting a “swamp the regulator” policy – bombarding the bodies that award drug licences with large numbers of “incomplete, partial, sub-standard clinical trials”.

One study of 111 final applications for approval found that 42 per cent were missing data from adequately randomised trials, 40 per cent were supported by flawed testing of dosages, 39 per cent lacked evidence of clinical efficacy, and 49 per cent raised concerns about serious adverse side-effects, he said.

In a statement, the Association of the British Pharmaceutical Industry (ABPI) said: “Professor Light is long on accusation and woefully short on hard evidence. There is now much greater transparency in clinical trial results. The UK pharmaceutical industry also adheres to a strict code of practice on the sales and marketing of its products.

“The patient information leaflet provided in every pack with a medicine details the side effects which have been reported in clinical trials and reviewed by the regulator.”

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in